News for Foghorn Therapeutics Inc. (FHTX)

Foghorn Therapeutics (FHTX) delivered earnings and revenue surprises of -3.45% and 75.63%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Foghorn Therapeutics (FHTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

On December 31, 2024, FMR LLC (Trades, Portfolio) executed a strategic transaction involving Foghorn Therapeutics Inc (FHTX), reducing its stake by 644,265 shar

Foghorn Therapeutics (FHTX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiat...

Foghorn Therapeutics (FHTX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

First-in-class oral selective SMARCA2 (BRM) inhibitor, FHD-909 (LY4050784), advancing in Phase 1 trial for SMARCA4 mutated cancers, with non-small cell lung can

Foghorn Therapeutics (FHTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Foghorn Therapeutics Inc. (FHTX), Monday said that it decided to discontinue the development of FHD-286 in combination with decitabine to treat patients with acute myeloid leukemia (AML).

**media[493316]**

The heavy selling pressure might have exhausted for Foghorn Therapeutics (FHTX) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.

Foghorn Therapeutics (FHTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

The mean of analysts' price targets for Foghorn Therapeutics (FHTX) points to a 104.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Brian M. Alexander Joins Valo Health as Chief Executive Officer and Flagship Pioneering as CEO-Partner

Revenue: Reported $7.8 million for Q3 2024, surpassing the analyst estimate of $6.34 million, driven by the Lilly Collaboration Agreement.Net Loss: Increased t

Shares of Nikola Corporation NKLA fell sharply in Monday's session after the company announced it entered into a securities purchase agreement and filed for a m...

BOULDER, Colo., Feb. 15, 2024 (GLOBE NEWSWIRE) -- OnKure, Inc. today announced the appointment of Samuel Agresta, M.D., M.P.H. as Chief Medical Officer....

/PRNewswire/ -- DelveInsight's 'Soft Tissue Sarcoma Pipeline Insight – 2023' report provides comprehensive global coverage of available, marketed, and pipeline...

Revenue in Q4 2022 decreased 9%. Excluding COVID-19 antibodies, revenue in Q4 2022 increased 5%, or 10% on a constant currency basis, driven by volume growth...